VCYT241220C22500
- 7.60
- 0.000.00%
Veracyte Newsroom
Insider Sale: VP of $VCYT (VCYT) Sells 5,032 Shares
Veracyte, Inc. (NASDAQ:VCYT) Held Back By Insufficient Growth Even After Shares Climb 30%
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
Veracyte Is Maintained at Underweight by Morgan Stanley
Veracyte Price Target Raised to $28.00/Share From $26.00 by Morgan Stanley
Express News | Veracyte Inc : Morgan Stanley Raises Target Price to $28 From $26
Sell Rating on Veracyte: Strong Performance Overshadowed by Limited Immediate Upside
Wolfe Research Initiates Veracyte(VCYT.US) With Buy Rating, Announces Target Price $50
Veracyte Initiated With an Outperform at Wolfe on Growth, Margin Potential
Veracyte Initiated With an Outperform at Wolfe Research
Veracyte Insider Sold Shares Worth $585,663, According to a Recent SEC Filing
ARKK's Holdings Ranked by SA Quant Grades
Leerink Partners Maintains Veracyte(VCYT.US) With Buy Rating, Maintains Target Price $50
Veracyte, Inc. Just Recorded A 296% EPS Beat: Here's What Analysts Are Forecasting Next
Scotiabank Maintains Veracyte(VCYT.US) With Buy Rating, Raises Target Price to $44
Scotiabank Reaffirms Their Buy Rating on Veracyte (VCYT)
A Quick Look at Today's Ratings for Veracyte(VCYT.US), With a Forecast Between $38 to $50
Veracyte Is Maintained at Buy by Goldman Sachs
Veracyte | 10-Q: Q3 2024 Earnings Report
Needham Maintains Veracyte(VCYT.US) With Buy Rating, Raises Target Price to $44